TW
REGN icon

TritonPoint Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

TritonPoint Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465K Buy
745
+64
+9% +$43.6K 0.05% 184
2026
Q1 		$526K Sell
681
-148
-18% -$113K 0.06% 165
2025
Q4 		$640K Sell
829
-1,938
-70% -$1.32M 0.06% 152
2025
Q3 		$1.56M Buy
2,767
+281
+11% +$159K 0.13% 125
2025
Q2 		$1.3M Sell
2,486
-69
-3% -$38.5K 0.12% 136
2025
Q1 		$1.62M Sell
2,555
-4
-0.2% -$2.75K 0.15% 127
2024
Q4 		$1.82M Sell
2,559
-145
-5% -$122K 0.17% 119
2024
Q3 		$2.82M Buy
2,704
+148
+6% +$165K 0.26% 95
2024
Q2 		$2.69M Buy
2,556
+92
+4% +$89.2K 0.26% 90
2024
Q1 		$1.92M Buy
2,464
+206
+9% +$196K 0.2% 108
2023
Q4 		$1.98M Buy
+2,258
New +$1.86M 0.19% 112

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TritonPoint Wealth's REGN Position: Q2 2026 in Review

TritonPoint Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 9.4% in Q2 2026, buying an estimated $43.6K and bringing the position to 745 shares worth $465K. The position accounts for 0.05% of the portfolio, ranked #184.

TritonPoint Wealth first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.82M in Q3 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • TritonPoint Wealth held 745 shares of Regeneron Pharmaceuticals worth $465K as of Q2 2026.
  • TritonPoint Wealth bought 64 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $43.6K.
  • Regeneron Pharmaceuticals made up 0.05% of TritonPoint Wealth's portfolio in Q2 2026, its #184 holding.
  • TritonPoint Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • TritonPoint Wealth's Regeneron Pharmaceuticals position peaked at $2.82M in Q3 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on TritonPoint Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.